Full Year Trading Update and Notice of Results

In brief · summary, not quotable

Oxford Nanopore Technologies plc anticipates reporting full-year 2025 revenue between £223 million and £224 million, representing approximately 22% growth on a reported basis and 24% at constant currency, slightly exceeding guidance. The company experienced broad-based growth across all geographies and customer end markets, with Clinical revenue up around 60%, BioPharma by 30%, and Applied Industrial by 27%, while Research revenue grew 15%. The PromethION range saw over 40% year-on-year growth. Oxford Nanopore ended 2025 with approximately £302 million in cash, cash equivalents, and liquid investments, ahead of expectations. The company will announce its preliminary annual results on March 2, 2026.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your ONT notes

The Group expects to report revenue of approximately £223 - £224 million (FY24: £183.2 million), representing growth of approximately 22% on a reported basis and 24% at constant currency, slightly ahead of the Group's guidance range of 20-23% constant currency growth.
Continued progress on path to profitability.

Broad-based growth across all geographies, customer end markets and product categories

Continued commercial momentum with revenue growth increasing by more than 20% constant currency across each region (EMEAI, APAC and AMR).
Across customer end markets, Clinical revenue grew by approximately 60% on a reported basis, BioPharma by approximately 30% and Applied Industrial by approximately 27%. Research revenue grew by approximately 15% during the period despite end-market funding pressures.1
Growth was delivered across all product types, led by the PromethION range, which grew by more than 40% year-on-year on a reported basis.

Business remains well capitalised to deliver on its goals

Oxford Nanopore ended the year with approximately £302 million in cash, cash equivalents and other liquid investments as at 31 December 2025 (FY24: £403.8 million), ahead of consensus expectations helped by improving working capital, providing continued balance sheet strength to support execution of the Group's strategy.

Notice of Results

Oxford Nanopore will announce its preliminary annual results for the twelve months ended 31 December 2025 on Monday 2 March 2026.
Management will host a virtual presentation on the same day at 9:30am GMT / 4:30am EST, followed by a Q&A session accessible via webcast and conference call.
The FY24 customer end market comparatives have been re-presented following a refinement of the data categorisation during the year. There has been no change to the overall FY24 revenue number however there has been a reclassification of £1.9 million from Applied Industrial and £1.0 million from BioPharma to the Research (£1.6 million) and Clinical (£1.3 million) markets.
Constant currency (CC) applies the same rate to the FY25 and FY24 non-GBP results based on FY24 rates.
All percentages compare to the equivalent 2024 period.
APAC: Asia Pacific, AMR: The Americas, EMEAI: Europe, the Middle East, Africa and India

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.